SCHEMBL20918153

SCHEMBL20918153

COc1ccc2c(=O)c(C(=O)O)c(-c3ccccc3Cl)oc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.54
KDM4E B2RXH2 9/20 0.54
MAPT P10636 5/20 0.54
HPGD P15428 4/20 0.54
MEN1 O00255 3/20 0.54
CYP3A4 P08684 3/20 0.54
KMT2A Q03164 3/20 0.54
HSD17B10 Q99714 3/20 0.54
THRB P10828 1/20 0.54
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
MAOA P21397 1/20 0.51
PIM1 P11309 1/20 0.49
CSNK2A2 P19784 1/20 0.49
CSNK2B P67870 1/20 0.49
PIM3 Q86V86 1/20 0.49
PIM2 Q9P1W9 1/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31723176 1.00 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL20918133 0.81 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL31723135 0.81 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL20918249 0.80 CA1 (0.51) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL31723141 0.80 CA1 (0.51) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL20918135 0.78 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL31723138 0.78 ALDH1A1 (0.52) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL31723148 0.77 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL28430712 0.77 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTHPGDMEN1
SCHEMBL20918138 0.76 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3699174-B1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2025-11-12 EP claimed
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2023-12-26 US claimed
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2023-03-30 US claimed
US-11504349-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2022-11-22 US claimed
EP-3699174-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2020-08-26 EP claimed
US-20200246304-A1 Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same ILAB (KR) 2020-08-06 US claimed
CN-111315730-A Composition for preventing or treating tumor necrosis factor-related diseases comprising novel derivative as active ingredient and method for inhibiting tumor necrosis factor activity using the same 艾伊莱布 2020-06-19 CN claimed
WO-2019078452-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME 가톨릭대학교 산학협력단 2019-04-25 WO claimed
EP-3699174-B1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2025-11-12 EP disclosed
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2023-12-26 US disclosed
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2023-03-30 US disclosed
US-11504349-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same ILAB (KR) 2022-11-22 US disclosed
EP-3699174-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2020-08-26 EP disclosed
US-20200246304-A1 Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same ILAB (KR) 2020-08-06 US disclosed
CN-111315730-A Composition for preventing or treating tumor necrosis factor-related diseases comprising novel derivative as active ingredient and method for inhibiting tumor necrosis factor activity using the same 艾伊莱布 2020-06-19 CN disclosed
WO-2019078452-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME 가톨릭대학교 산학협력단 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11850230-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same TNF, NFKBIA, TRAF6 ALDH1A1 2334/4885KDM4E 2226/4885MAPT 2554/4885
US-20230099574-A1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME TNF, NFKBIA, TRAF6 ALDH1A1 2334/4885KDM4E 2226/4885MAPT 2554/4885
US-20200246304-A1 Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same TNF, NFKBIA, TRAF6 ALDH1A1 2334/4885KDM4E 2226/4885MAPT 2554/4885
US-11504349-B2 Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same TNF, NFKBIA, TRAF6 ALDH1A1 2334/4885KDM4E 2226/4885MAPT 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.